FDA warned Try Nova that its website’s compounded semaglutide claim "Same active ingredient as Wegovy & Ozempic" is false or misleading.
What happened
FDA reviewed https://trynovamd.com in August 2025 and found it offered compounded (custom-mixed) drug products, including semaglutide, with the claim "Same active ingredient as Wegovy & Ozempic." FDA says compounded drugs are not FDA-approved, so the claim is false or misleading and the products are misbranded (falsely labeled or advertised).
What FDA found
The website claim that compounded semaglutide has the same active ingredient as Wegovy and Ozempic is false or misleading because compounded drugs are not FDA-approved.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The company introduced or delivered these falsely labeled or advertised products into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving falsely labeled or advertised drugs in interstate commerce, and delivering or offering to deliver them, is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days of receipt, Try Nova must send a written response to FDA’s Office of Compounding Quality and Compliance describing steps taken to fix the violations, prevent recurrence, and include supporting documents. If it disagrees or cannot complete the work in time, it must explain why and give a timeline.
Who should pay attention
- telehealth companies selling compounded semaglutide
- compounding pharmacies and their marketing partners
- platforms that compare compounded drugs to FDA-approved brand products
This is a summary. Read the original letter on fda.gov.